News
-
-
PRESS RELEASE
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
FSD Pharma submits a clinical trial application for Lucid-21-302, a neuroprotective compound for multiple sclerosis treatment, to an Australian ethics review committee -
-
PRESS RELEASE
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
FSD Pharma partners with ASPI to conduct a study on unbuzzd™, a supplement for alcohol intoxication. The study aims to assess safety and efficacy in healthy volunteers -
-
-
-
PRESS RELEASE
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
FSD Pharma Inc. provides an update on the launching of unbuzzd™, an innovative beverage product scientifically formulated to support the body's natural processes for metabolizing alcohol and promoting alertness in collaboration with BevSource -
-
PRESS RELEASE
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
FSD Pharma expands pipeline into metabolic and related disorders, focusing on weight loss and liver health solutions. Company aims to create new products to address ailments affecting millions worldwide
